Primary Site >> Biliary tract Cancer

Gene >> HDAC9

Journal: World J Gastroenterol. 2007 Sep 7;13(33):4458-66.
Title: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Author: Baradari, Viola|Hopfner, Michael|Huether, Alexander|Schuppan, Detlef|Scherubl, Hans
PMID: 17724801
Journal: Surgery. 2012 Mar;151(3):412-9.
Title: Role of histone deacetylase expression in intrahepatic cholangiocarcinoma.
Author: Morine, Yuji|Shimada, Mitsuo|Iwahashi, Shuichi|Utsunomiya, Tohru|Imura, Satoru|Ikemoto, Tetsuya|Mori, Hiroki|Hanaoka, Jun|Miyake, Hidenori
PMID: 21982637
Journal: Invest New Drugs. 2018 Jul 11. pii: 10.1007/s10637-018-0634-5.
Title: Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Author: Ikeda, Masafumi|Ohno, Izumi|Ueno, Hideki|Mitsunaga, Shuichi|Hashimoto, Yusuke|Okusaka, Takuji|Kondo, Shunsuke|Sasaki, Mitsuhito|Sakamoto, Yasunari|Takahashi, Hideaki|Hara, Rina|Kobayashi, Shingo|Nakamura, Osamu|Morizane, Chigusa
PMID: 29995287